Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Anglesio, Michael S., George, Joshy, Kulbe, Hagen, Friedlander, Michael, Rischin, Danny, Lemech, Charlotte, Power, Jeremy, Coward, Jermaine, Cowin, Prue A., House, Colin M., Chakravarty, Probir, Gorringe, Kylie L., Campbell, Ian G., Australian Ovarian Cancer Study Group, Okamoto, Aikou, Birrer, Michael J., Huntsman, David G., de Fazio, Anna, Kalloger, Steve E., Balkwill, Frances, Gilks, C. Blake, Bowtell, David D.·2011·Clinical Cancer Research

Abstract

Purpose: Ovarian clear cell adenocarcinoma (OCCA) is an uncommon histotype that is generally refractory to platinum-based chemotherapy. We analyze here the most comprehensive gene expression and copy number data sets, to date, to identify potential therapeutic targets of OCCA. Experimental Design: Gene expression and DNA copy number were carried out using primary human OCCA tumor samples, and findings were confirmed by immunohistochemistry on tissue microarrays. Circulating interleukin (IL) 6 levels were measured in serum from patients with OCCA or high-grade serous cancers and related to progression-free and overall survival. Two patients were treated with sunitinib, and their therapeutic responses were measured clinically and by positron emission tomography. Results: We find specific overexpression of the IL6-STAT3-HIF (interleukin 6-signal transducer and activator of transcription 3-hypoxia induced factor) pathway in OCCA tumors compared with high-grade serous cancers. Expression of PTHLH and high levels of circulating IL6 in OCCA patients may explain the frequent occurrence of hypercalcemia of malignancy and thromboembolic events in OCCA. We describe amplification of several receptor tyrosine kinases, most notably MET, suggesting other potential therapeutic targets. We report sustained clinical and functional imaging responses in two OCCA patients with chemotherapy-resistant disease who were treated with sunitinib, thus showing significant parallels with renal clear cell cancer. Conclusions: Our findings highlight important therapeutic targets in OCCA, suggest that more extensive clinical trials with sunitinib in OCCA are warranted, and provide significant impetus to the growing realization that OCCA is molecularly and clinically distinct to other forms of ovarian cancer. Clin Cancer Res; 17(8); 2538–48. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-3314

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 258

Metadata

Authors
Anglesio, M. S., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P. A., House, C. M., Chakravarty, P., Gorringe, K. L., Campbell, I. G., Australian Ovarian Cancer Study Group, Okamoto, A., Birrer, M. J., Huntsman, D. G., de Fazio, A., Kalloger, S. E., Balkwill, F., Gilks, C. B., & Bowtell, D. D.
Venue
Clinical Cancer Research
Published
2011-04-14
Volume
17
Issue
8
Pages
2538-2548
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2067841857
Cited by
258
References
54
FWCI
27.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3314
The paper
Anglesio, M. S., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P. A., House, C. M., Chakravarty, P., Gorringe, K. L., Campbell, I. G., Australian Ovarian Cancer Study Group, Okamoto, A., Birrer, M. J., Huntsman, D. G., de Fazio, A., Kalloger, S. E., . . . Bowtell, D. D. (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.